AACR 2023 | The importance of elucidating the right biomarkers in phase I oncology trials

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on incorporating biomarkers in early stage clinical trials. Pharmacodynamic biomarkers are critical to evaluate the best dosage and mechanism of action of the investigational therapy. Dr Yap additionally highlights the need to have predictive biomarkers of response. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.